Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease (RODEO)

• Circulatory proinflammatory markers [ Time Frame: 3 months ] [ Designated as safety issue: No ]
• FEV1 and FEV1/FVC ratio [ Time Frame: 3 months ] [ Designated as safety issue: No ]

• Circulatory proinflammatory markers [ Time Frame: 3 months ] [ Designated as safety issue: No ]
• Leucocyte count in sputum [ Time Frame: 3 months ] [ Designated as safety issue: No ]
• FEV1 and FEV1/FVC ratio [ Time Frame: 3 months ] [ Designated as safety issue: No ]

The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary disease.

• Drug: Rosuvastatin
  10mg tablets, once daily in three months
  Other Name: Hydroxymethylglutaryl-CoA Reductase Inhibitor
• Drug: Placebo
  1 tablet, once daily in three months

• Experimental: Rosuvastatin
  Intervention: Drug: Rosuvastatin
• Placebo Comparator: Placebo
  Intervention: Drug: Placebo

Inclusion criteria:

• Stable COPD patients of both genders with no COPD exacerbations less than three weeks prior to inclusion
• COPD stage I to IV after the GOLD criteria (Global Initiative for Chronic Obstructive Lung Disease)
• Age between 40 and 80 years

Exclusion criteria:

• Diagnosed lung disease other than COPD, except chronic asthmatic bronchitis and mild bronchiectasis without or few physical signs (diagnosed by high resolution CT)
• History of or active coronary artery disease (CAD), cerebrovascular or peripheral vascular disease
• History of or clinically significant congestive heart failure, valvular heart disease, clinically significant arrhythmias or conduction delays
• History of uncontrolled arterial hypertension (defined as blood pressure above180/110 mmHg with or without the use of antihypertensive medication)
• Body mass index >40kg/m2
• History of diabetes mellitus, measured fasting glucose > 11 mmol/L
• History of Hypercholesterolemia, measured total cholesterol > 8 mmol/L
• Known poliomyelitis, motor neurone disease, cranial or temporal arteritis, stroke or myopathy
• Neutropenia, anemia (Hb < 8 g/100mL)
• History of chronic renal failure, serum creatinine > 176 micromol/L (2.0mg/dL)
• Creatine kinase > 3 times the upper limit of normal (ULN)
• Acute or chronic liver disease (serum transaminases > 3 times the ULN)
• Pregnancy (oral examination and blood test prior to inclusion)
• Active abuse of drugs or alcohol, poor compliance anticipated
• Statin use within the last 4 weeks prior to study start or previously clear indication for statin use
• Prior diagnosis of statin induced myopathy or hypersensitivity reaction to another HMG-CoA-reductase inhibitor incl. Rosuvastatin
• History of malignant disease of any kind within 5 years prior to inclusion.
• History of uncontrolled hypothyroidism
• Participation in another pharmaceutical or medical device clinical trial study less than 4 weeks prior inclusion.
• Use concomitant of medications that are known to interact with Crestor. This includes the following medications: Warfarin and other coumarin (vitamin K antagonist) anticoagulants, Cyclosporin, Gemfibrozil and Antacid

• AstraZeneca
• Haukeland University Hospital